Equine Atg

Lymphoma, Non-Hodgkin

Instituto Nacional de Cancer, BrazilPhase 3Active

B

62/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 56/ 100
Competitive Position: 73/ 100

Competitive context

98 Active assets in the Lymphoma, Non-Hodgkin cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide National Cancer Institute (NCI)	Phase 3	BB
Plerixafor Thomas Jefferson University	Phase 4	BB
METHOTREXATE Sun Yat-sen University	Phase 3	BB
Cytosin-Arabinosid Mwanasha Merrill, MD	Phase 3	BB
Obinutuzumab National Cancer Institute (NCI)	Phase 3	BB

View all 50 →

Same molecule, other indications

Equine Atg is also rated in:

acute lymphoblastic leukemiaDormant

BBB

Indicative ·

72 / 100

disease related to hematopoietic stem cell transplantDormant

BB

Indicative ·

68 / 100

Hemoglobinuria, Paroxysmal Nocturnal (PNH)Dormant

BB

Indicative ·

67 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.